NL301185I2 - Combinatie van daunorubicine en cytarabine - Google Patents
Combinatie van daunorubicine en cytarabineInfo
- Publication number
- NL301185I2 NL301185I2 NL301185C NL301185C NL301185I2 NL 301185 I2 NL301185 I2 NL 301185I2 NL 301185 C NL301185 C NL 301185C NL 301185 C NL301185 C NL 301185C NL 301185 I2 NL301185 I2 NL 301185I2
- Authority
- NL
- Netherlands
- Prior art keywords
- cytarabine
- daunorubicin
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90177207P | 2007-02-16 | 2007-02-16 | |
US96519607P | 2007-08-17 | 2007-08-17 | |
PCT/US2008/054168 WO2008101214A2 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
EP08730048.9A EP2120568B1 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NL301185I2 true NL301185I2 (nl) | 2022-07-21 |
Family
ID=39690832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL301185C NL301185I2 (nl) | 2007-02-16 | 2022-07-05 | Combinatie van daunorubicine en cytarabine |
Country Status (20)
Country | Link |
---|---|
US (2) | US8092828B2 (nl) |
EP (3) | EP4046640A1 (nl) |
JP (1) | JP5314600B2 (nl) |
KR (2) | KR20100014441A (nl) |
CN (1) | CN105998046A (nl) |
AU (1) | AU2008216083B2 (nl) |
CA (1) | CA2678332C (nl) |
CY (1) | CY1119631T1 (nl) |
DK (2) | DK3300601T3 (nl) |
ES (2) | ES2650167T3 (nl) |
FR (1) | FR22C1034I2 (nl) |
HK (1) | HK1253378A1 (nl) |
HR (1) | HRP20220428T3 (nl) |
HU (2) | HUE058334T2 (nl) |
NL (1) | NL301185I2 (nl) |
NO (1) | NO2120568T3 (nl) |
PL (2) | PL3300601T3 (nl) |
PT (2) | PT3300601T (nl) |
SI (1) | SI3300601T1 (nl) |
WO (1) | WO2008101214A2 (nl) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100075937A1 (en) * | 2008-09-24 | 2010-03-25 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
EP2768484B1 (en) | 2011-10-21 | 2019-07-24 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
US20140154304A1 (en) * | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2017083592A1 (en) | 2015-11-11 | 2017-05-18 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2019023873A1 (zh) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 |
AU2019350759A1 (en) * | 2018-09-25 | 2021-04-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
AU2019394855A1 (en) | 2018-12-04 | 2021-06-24 | Der-Yang Tien | Stereocomplexes for the delivery of anti-cancer agents |
BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
NZ540384A (en) * | 2002-11-06 | 2008-06-30 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
EP1575582A4 (en) * | 2002-11-06 | 2009-03-11 | Wyeth Corp | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME |
US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
US8022279B2 (en) * | 2004-04-22 | 2011-09-20 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
-
2008
- 2008-02-15 HR HRP20220428TT patent/HRP20220428T3/hr unknown
- 2008-02-15 PT PT172004988T patent/PT3300601T/pt unknown
- 2008-02-15 PL PL17200498T patent/PL3300601T3/pl unknown
- 2008-02-15 CA CA2678332A patent/CA2678332C/en active Active
- 2008-02-15 EP EP22150734.6A patent/EP4046640A1/en active Pending
- 2008-02-15 WO PCT/US2008/054168 patent/WO2008101214A2/en active Application Filing
- 2008-02-15 ES ES08730048.9T patent/ES2650167T3/es active Active
- 2008-02-15 CN CN201610324431.2A patent/CN105998046A/zh active Pending
- 2008-02-15 SI SI200832194T patent/SI3300601T1/sl unknown
- 2008-02-15 PL PL08730048T patent/PL2120568T3/pl unknown
- 2008-02-15 HU HUE17200498A patent/HUE058334T2/hu unknown
- 2008-02-15 DK DK17200498.8T patent/DK3300601T3/da active
- 2008-02-15 KR KR1020097019393A patent/KR20100014441A/ko active Application Filing
- 2008-02-15 ES ES17200498T patent/ES2909903T3/es active Active
- 2008-02-15 AU AU2008216083A patent/AU2008216083B2/en active Active
- 2008-02-15 NO NO08730048A patent/NO2120568T3/no unknown
- 2008-02-15 EP EP08730048.9A patent/EP2120568B1/en not_active Revoked
- 2008-02-15 US US12/032,583 patent/US8092828B2/en active Active
- 2008-02-15 DK DK08730048.9T patent/DK2120568T3/en active
- 2008-02-15 JP JP2009550160A patent/JP5314600B2/ja active Active
- 2008-02-15 PT PT87300489T patent/PT2120568T/pt unknown
- 2008-02-15 US US12/526,930 patent/US20100303895A1/en not_active Abandoned
- 2008-02-15 KR KR20157007810A patent/KR20150038752A/ko active Search and Examination
- 2008-02-15 EP EP17200498.8A patent/EP3300601B1/en active Active
-
2017
- 2017-11-29 CY CY20171101251T patent/CY1119631T1/el unknown
-
2018
- 2018-10-03 HK HK18112675.7A patent/HK1253378A1/zh unknown
-
2022
- 2022-07-05 NL NL301185C patent/NL301185I2/nl unknown
- 2022-07-05 FR FR22C1034C patent/FR22C1034I2/fr active Active
- 2022-07-07 HU HUS2200032C patent/HUS2200032I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301185I2 (nl) | Combinatie van daunorubicine en cytarabine | |
NL300960I2 (nl) | Combinatie van daunorubicine en cytarabine | |
NO2020028I1 (no) | saksagliptin og dapagliflozin | |
NL301016I1 (nl) | Combinatie van daunorubicine en cytarabine | |
BRPI0809103A2 (pt) | composições de magnésio e seus usos | |
DE602007009504D1 (de) | Ballontrokar | |
DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
BRPI0906735A2 (pt) | Terapia de combinação que compreende inibidores de sglt e inibidores de dpp4 | |
BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
BRPI0906980A2 (pt) | Composição de derivados e maleatados | |
BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
DE602007010795D1 (de) | Blattsauger und -häcksler | |
BRPI0807495A2 (pt) | Adjuvantes e métodos de emrpego dos mesmos | |
IL212199A0 (en) | Hpma- docetaxel or gemcitabine conjugates and uses therefore | |
BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
BRPI0816428A2 (pt) | Folha de vidro e utilização da folha de vidro | |
BRPI0817269A2 (pt) | Análogos de azacitidina e usos dos mesmos | |
BRPI0716466A2 (pt) | Tratamento da calda de açúcar | |
EP2064300A4 (en) | ADHESIVE FABRIC COMPOSITIONS AND RELATED METHODS | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
BRPI0806964A2 (pt) | Combinações de agonístico beta-2-adrenoceptor e benzotiazolona | |
BRPI0821106A2 (pt) | Pró-fármacos de nucleosídeo e usos dos mesmos | |
BRPI0812932A2 (pt) | Composições e métodos de tratar câncer | |
BRPI0814876A2 (pt) | Análogos de pirona fosforilados e métodos | |
BRPI0907561A2 (pt) | Materiais e métodos para aperfeiçoamento da saúde de camarões |